Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Jefferies analyst Brian Tanquilut lowered the firm’s price target on Walgreens Boots Alliance (WBA) to $9 from $19 and keeps ...
Both the CDC and the FDA warn against treating this common childhood condition on your own with non-prescription treatments. See what they recommend.